Table 2.
Body composition evaluation details; chemotherapy administered and association of body composition to chemo-related toxicity (if any).
| Authors | Vertebra level for body composition assessment | Body composition features evaluated | Chemotherapy | Association of body composition and chemo-related toxicity |
|---|---|---|---|---|
| Prado (29) | L3 | SMD; LBM; FM | Pegylated liposomal doxorubicina | FM/LBM ratio associated with toxicity only in overweight and obese patients |
| Yoshikawa (28) | L5 | PI | Carboplatin and paclitaxel | PI associated with neuropathy |
| Conrad (27) | L4 | PA; PI, VAT, SAT | Carboplatin and paclitaxel | No association |
| Staley (25) | L3 | SMA, SMI | Carboplatin and paclitaxel | No association |
| Bruno (26) | L3 | SMI, SAT, SMD | Carboplatin and paclitaxel | SAT and SMD associated with G3 adverse events and toxicity-induced modification of treatment |
| Del Grande (12) | L3 | SMA, SMI, VAT, SAT, SMD | Carboplatin and paclitaxel | VAT and SMD associated with chemotherapy cycle delays; SMA with early discontinuation of chemotherapy |
L3, 3rd lumbar vertebra; L4, 4th lumbar vertebra; L5, 5th lumbar vertebra; SMA, skeletal muscle area; SMI, skeletal muscle index; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; SMD, skeletal muscle density; PA, psoas area; PI, psoas index; LBM, lean body mass; FM, fat mass; G3, grade 3.